Vitamin D and Vascular Health in Children
Vitamin D and Vascular Function in Obese Children
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Our primary objective is to determine, in obese and overweight children aged 10 to 18 years with vitamin D deficiency (defined as serum 25-hydroxyvitamin D <20 ng/mL), the efficacy of enhanced vitamin D3 supplementation in improving vascular endothelial function, arterial stiffness, insulin sensitivity, and metabolic syndrome risk status; and to assess whether these effects are dose-dependent. As a secondary objective, we will examine the vitamin D supplementation-induced effect on adipokines and inflammatory markers relevant to CVD risk. In a double-masked, controlled trial, we will randomize 252 eligible children to receive either 600 IU (conventional supplementation), or 1000 IU or 2000 IU (enhanced supplementation) of vitamin D3 daily for 6 months.
In terms of reporting of results, the following pre-specified outcomes are included in the primary manuscript (PubMed PMID:31950134 -- see Reference section for citation details)
- Waist Circumference
- Serum High Density Lipoprotein (HDL) Cholesterol
- Serum Triglycerides
- Inflammatory markers (Plasma TNF-alpha, high-sensitivity C-reactive protein, and IL-6)
- Adiopkines (Plasma Leptin and Adiponectin)
Plasma nitric oxide metabolites were not measured.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213
- Primary Care Center, Children's Hospital of Pittsburgh of UPMC
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Eligible subjects will be 10 to 18 years of age;
- obese or overweight (BMI ≥85th %tile);
- otherwise healthy, and
- have a serum 25(OH)D concentration <20 ng/mL
Children taking multivitamins should be able to hold off their multivitamins during the course of the study.
Exclusion Criteria:
Children will be excluded if they
- (a) have hepatic or renal disease, metabolic rickets, malabsorptive disorders, primary hyperparathyroidism, hyperthyroidism, or other chronic disorders that could affect vitamin D metabolism;
- (b) are receiving treatment with anticonvulsants, systemic glucocorticoids, pharmacologic doses of vitamin D (≥1000 IU of vitamin D2 or D3 daily), antihypertensives, vasoactive drugs, antilipidemics, metformin, antipsychotics, or other oral insulin regulators;
- (c) have cholelithiasis or urolithiasis;
- (d) have type 1 or type 2 diabetes; or
- (e) have a condition or underlying abnormality that could compromise the safety of the subject.
Post-menarchial girls with a positive pregnancy test at randomization, or subjects found during the screening phase to have hypercalcemia (serum calcium >10.8 mg/dL) or significant fasting hyperglycemia (fasting blood glucose ≥ 125 mg/dL) will also be excluded.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Vitamin D3 2000 IU
Vitamin D3 2000 IU tablet once daily by mouth for 6 months
|
Tablet form
Otros nombres:
|
|
Comparador activo: Vitamin D3 1000 IU
Vitamin D3 1000 IU tablet by mouth once daily for 6 months
|
Tablet form
Otros nombres:
|
|
Comparador de placebos: Vitamin D3 600 IU
Vitamin D3 600 IU tablet by mouth once daily for 6 months
|
Tablet form
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Flow-mediated Dilation (FMD) Percentage
Periodo de tiempo: 6 months
|
Brachial artery flow-mediated dilation percentage is a measure of endothelial function.
FMD percentage calculation is based on baseline brachial artery diameter(brachialADbase) and change in brachial artery diameter (brachialADchange) during post-occlusive reactive hyperemia.
FMD% was determined using the formula (brachialADchange/brachialADbase) x 100.
|
6 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Pulse-wave Velocity (PWV)
Periodo de tiempo: 6 months
|
PWV is a measure of arterial stiffness.
Higher values of PWV indicate greater degree of arterial stiffness.
|
6 months
|
|
Augmentation Index at Heart Rate of 75 Beats/Min (AIx-75)
Periodo de tiempo: 6 months
|
AIx-75 is a measure of arterial stiffness. AIx was measured through radial arterial tonometry using SphygmoCor. Radial pulse waveform are analyzed through an automatic software function to determine aortic pulse waveform and aortic or central systolic (cSBP) and diastolic blood pressure (cDBP), and these measurements are further analyzed automatically to calculate AIx. AIx is a composite measure of the magnitude of wave reflection and arterial stiffness in all conduit arteries which affect the timing of the wave reflection. AIx = P2-P1/cSBP-cDBP, where P1 is the height of the incident pressure wave form during systole, P2 is the height of the reflected wave added to the incident wave, cSBP is the aortic systolic BP, and cDBP is the aortic diastolic BP. AIx adjusted to heart rate of 75 beats/min (AIx-75) is a validated index of arterial stiffness, with higher values indicating higher degree of arterial stiffness. |
6 months
|
|
Central Systolic Blood Pressure
Periodo de tiempo: 6 months
|
a measure of cardiometabolic health
|
6 months
|
|
Central Diastolic Blood Pressure
Periodo de tiempo: 6 months
|
a measure of cardiometabolic health
|
6 months
|
|
Systemic Systolic Blood Pressure
Periodo de tiempo: 6 months
|
a measure of cardiometabolic health
|
6 months
|
|
Systemic Diastolic Blood Pressure
Periodo de tiempo: 6 months
|
a measure of cardiometabolic health
|
6 months
|
|
Fasting Blood Glucose
Periodo de tiempo: 6 months
|
a measure of cardiometabolic health
|
6 months
|
|
1/Fasting Insulin Ratio
Periodo de tiempo: 6 months
|
1/fasting insulin ratio is a measure of insulin sensitivity.
Increases in 1/fasting insulin ratio indicate improvements in insulin sensitivity.
|
6 months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Body Mass Index (BMI)
Periodo de tiempo: 6 months
|
a surrogate measure of adiposity
|
6 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Kumaravel Rajakumar, MD, MS, University of Pittsburgh, Children's Hospital of Pittsburgh of UPMC
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- PRO12100034
- R01HL112985 (Subvención/contrato del NIH de EE. UU.)
- 5R01HL112985-05 (Subvención/contrato del NIH de EE. UU.)
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .